- Vir Biotechnology Inc VIR changed the research cooperation agreement with GSK plc GSK in 2020.
- Vir will continue its ongoing efforts to discover, develop and advance COVID-19 solutions and other potential coronavirus outbreaks. independently or with other partners.
- The companies will continue to work to ensure continued access to sotrovimab for patients worldwide, if approved, and to develop new therapies for influenza and other respiratory diseases.
- In August 2022, Vir and GSK said they do not plan to submit a marketing application for sotrovimab for COVID-19, citing the development COVID-19 Landscape and FDA Discussions.
- In April 2022, the FDA said the companies’ sotrovimab was no longer approved for the treatment of COVID-19 in any US region due to an increase in the number of COVID-19 cases Omicron BA.2 subvariant.
- In April 2020, GSK and Vir collaborated to research and develop solutions to coronavirus.
- In 2021, the companies expanded their collaboration to research and develop new therapies against influenza and other respiratory viruses.
- Under the terms of the new amended agreement, Vir retains sole rights to the solutions resulting from the joint coronavirus vaccine and antibody programs, subject to tiered low to mid single digit royalties to GSK.
- Price promotion: VIR shares are down 1.53% to $25.78 and GSK shares are up 0.17% to $36.28 during the premarket session last Check Tuesday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
[ad_2]
Source story
